Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis

• Autorzy: Zhao J.J. , Lou X.L. , Chen H. , Zhu F. , Hou Y.Q.
• Języki publikacji: EN

Abstrakty

EN

The levels of decoy receptor 3 (DcR3), soluble urokinase type plasminogen activator receptor (suPAR) and procalcitonin (PCT) are significantly increased in sepsis. We investigated the diagnostic value of DcR3 combined with suPAR and PCT in sepsis. Patients with sepsis, non-infectious systemic inflammatory response comprehensive syndrome (SIRS) and healthy controls were recruited according to the diagnostic standard. We measured DcR3, suPAR, PCT, interleukin-6 (IL-6) and C-reactive protein (CRP), and the diagnostic value was evaluated by receiver operating characteristics (ROC) curves. In our analysis, serum DcR3, suPAR and PCT levels of the sepsis group were significantly higher than those of the SIRS and control groups. However, IL-6, CRP and WBC showed no significant difference between the SIRS group and the sepsis group. The serum DcR3 level was positively correlated with the serum suPAR level (r = 0.37, p = 0.0022) and PCT level (r = 0.37, p = 0.0021). Using DcR3, suPAR and PCT to distinguish SIRS from sepsis, the area under the curve (AUC) values were 0.892, 0.778 and 0.692. When DcR3, suPAR and PCT combined were used for diagnosis of sepsis, the AUC was 0.933, at a cut-off point of 0.342. This combination improved the sensitivity and specificity of diagnosis of sepsis, suggesting that use of the combination of three indexes enhanced the efficiency of sepsis diagnosis.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2018
• Tom: 23
• Opis fizyczny: p.1-10,fig.,ref.

Twórcy

autor

Zhao J.J.

• Department of Central Laboratory, Songjiang Hospital Affiliated First People’s Hospital, Shanghai Jiao Tong University, Shanghai 201600, China

autor

Lou X.L.

• Department of Central Laboratory, Songjiang Hospital Affiliated First People’s Hospital, Shanghai Jiao Tong University, Shanghai 201600, China

autor

Chen H.

• Department of Central Laboratory, Songjiang Hospital Affiliated First People’s Hospital, Shanghai Jiao Tong University, Shanghai 201600, China

autor

Zhu F.

• Department of Central Laboratory, Songjiang Hospital Affiliated First People’s Hospital, Shanghai Jiao Tong University, Shanghai 201600, China

autor

Hou Y.Q.

• Department of Central Laboratory, Songjiang Hospital Affiliated First People’s Hospital, Shanghai Jiao Tong University, Shanghai 201600, China

Bibliografia

• 1. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. AJRCCM. 2016;193:259–72.
• 2. Lagu T, Rothberg MB, Shieh MS, et al. Hospitalizations, costs and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med. 2012;40:754–61.
• 3. Klouche M, Schröder U. Rapid methods for diagnosis of bloodstream infections. Clin Chem Lab Med. 2008;46:888–908.
• 4. Hsieh SL, Lin WW. Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. J Biomed Sci. 2017;24:39–47.
• 5. Kim S, Fotiadu A, Kotoula V. Increased expression of soluble decoy receptor 3 inacutely inflamed intestinal epithelia. Clin Immunol. 2005;115:286–94.
• 6. Hou YQ, Xu P, Zhang M, et al. Serum decoy 3, a potential new biomarker for sepsis. Clin Chim Acta. 2012;413:744–8.
• 7. Kim S, Mi L, Zhang L. Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis. Diagn Microbiol Infect Dis. 2012;73:312–7.
• 8. Hu C, Zhou Y, Liu C, et al. Pentraxin-3, procalcitonin and lactate as prognostic markers in patients with sepsis and septic shock. Oncotarget. 2017;9:5125–36.
• 9. Donadello K, Scolletta S, Covajes C. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10:2.
• 10. Henriquez-Camacho C, Losa J. Biomarkers for sepsis. Biomed Res Int. 2014;2014:547818.
• 11. Bloos F, Reinhart K. Rapid diagnosis of sepsis. Virulence. 2014;5:154–60.
• 12. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2013;39:165–228.
• 13. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest. 1992;101:1644–55.
• 14. Herzum I, Renz H. Inflammatory indicators in SIRS, sepsis and septic shock. Curr Med Chem. 2008;15:581–7.
• 15. Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as indicators of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11:R49.
• 16. O'Shea TM, Shah B, Allred EN, et al. Inflammation-initiating illnesses, inflammation-related proteins, and cognitive impairment in extremely preterm infants. Brain Behav Immun. 2013;29:104–12.
• 17. Biron BM, Ayala A, Lomas-Neira JL. Biomarkers for sepsis: what is and what might be? Biomark Insights. 2015;10:7–17.
• 18. Khakpour S, Wilhelmsen K, Hellman J. Vascular endothelial cell toll-like receptor pathways in sepsis. Innate Immun. 2015;21:744–8.
• 19. Shum HP, Yan WW, Chan TM. Recent knowledge on the pathophysiology of septic acute kidney injury: a narrative review. J Crit Care. 2016;31:82–9.
• 20. Ugarte H, Silva E, Mercan D, et al. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med. 1999;27:498–504.
• 21. Ruokonen E, Nousiainen T, Pulkki K, et al. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999;18:283–5.
• 22. Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESICM systematic review and meta-analysis of procalcitoninguided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med. 2012;38:940–9.
• 23. Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic indicator for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426–35.
• 24. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.
• 25. Gustafsson A, Ljunggren L, Bodelsson M, et al. The prognostic value of suPAR compared to other inflammatory indicators in patients with severe sepsis. Biomark Insights. 2012:739–44. https://doi.org/10.4137/BMI.S9460.
• 26. Gumus A, Altintas N, Cinarka H, et al. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:357–65.
• 27. Huttunen R, Syrjanen J, Vuento R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med. 2011;270:32–40.
• 28. Yilmaz G, Koksal I, Karahan SC, et al. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem. 2011;44:1227–30.
• 29. Molkanen T, Ruotsalainen E, Thorball CW, et al. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus—bacteremia. Eur J Clin Microbiol Infect Dis. 2011;30:14–24.
• 30. Ostrowski SR, Plomgaard P, Fischer CP, et al. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol. 2005;61:197–206.
• 31. Zeng M, Chang M, Zheng H, et al. Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis. Am J Emerg Med. 2016;34:375–80.
• 32. Chen MH, Kan HT, Liu CY, et al. Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients. J Formos Med Assoc. 2017;116:49–56.
• 33. Cheng CP, Sytwu HK, Chang DM. Decoy receptor 3 attenuates collagen-induced arthritis by modulating T cell activation and B cell expansion. J Rheumatol. 2011;38:2522–35.
• 34. Liang D, Hou Y, Lou X, et al. Decoy receptor 3 improves survival in experimental sepsis by suppressing the inflammatory response and lymphocyte apoptosis. PLoS One. 2015;e0131680:10.
• 35. Chang YC, Chen TC, Lee CT, et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood. 2008;1111:5054–63.
• 36. Liqin G, Bin Y, Hairong Z, et al. DcR3, a new biomarker for sepsis, correlates with infection severity and procalcitonin. Oncotarget. 2018;9:10934–44.

Identyfikatory

DOI

10.1186/s11658-018-0087-z